Next Article in Journal
Relaxation Dynamics of Chlorophyll b in the Sub-ps Ultrafast Timescale Measured by 2D Electronic Spectroscopy
Previous Article in Journal
Para-Halogenation of Amphetamine and Methcathinone Increases the Mitochondrial Toxicity in Undifferentiated and Differentiated SH-SY5Y Cells

COVID-19 Drug Discovery Using Intensive Approaches

Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan
Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Artificial Intelligence Research Center, Institute of Scientific and Industrial Research, Osaka University, 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
Department of Clinical and Molecular Medicine, University of Rome “Sapienza”, Santo Andrea Hospital, via di Grottarossa, 1035-00189 Rome, Italy
Unitech Co., Ltd., Kashiwa 277-0005, Japan
Kyowa-kai Medical Corporation, Osaka 540-0008, Japan
Prophoenix Division, Food and Life-Science Laboratory, Idea Consultants, Inc., Osaka-City, Osaka 559-8519, Japan
Kinshu-Kai Medical Corporation, Osaka 558-0041, Japan
Hirotsu Bio Science Inc., Tokyo 107-0062, Japan
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(8), 2839;
Received: 27 March 2020 / Revised: 9 April 2020 / Accepted: 14 April 2020 / Published: 18 April 2020
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable. View Full-Text
Keywords: COVID-19; coronavirus; infection; drug discovery; drug repositioning COVID-19; coronavirus; infection; drug discovery; drug repositioning
Show Figures

Figure 1

MDPI and ACS Style

Asai, A.; Konno, M.; Ozaki, M.; Otsuka, C.; Vecchione, A.; Arai, T.; Kitagawa, T.; Ofusa, K.; Yabumoto, M.; Hirotsu, T.; Taniguchi, M.; Eguchi, H.; Doki, Y.; Ishii, H. COVID-19 Drug Discovery Using Intensive Approaches. Int. J. Mol. Sci. 2020, 21, 2839.

AMA Style

Asai A, Konno M, Ozaki M, Otsuka C, Vecchione A, Arai T, Kitagawa T, Ofusa K, Yabumoto M, Hirotsu T, Taniguchi M, Eguchi H, Doki Y, Ishii H. COVID-19 Drug Discovery Using Intensive Approaches. International Journal of Molecular Sciences. 2020; 21(8):2839.

Chicago/Turabian Style

Asai, Ayumu, Masamitsu Konno, Miyuki Ozaki, Chihiro Otsuka, Andrea Vecchione, Takahiro Arai, Toru Kitagawa, Ken Ofusa, Masami Yabumoto, Takaaki Hirotsu, Masateru Taniguchi, Hidetoshi Eguchi, Yuichiro Doki, and Hideshi Ishii. 2020. "COVID-19 Drug Discovery Using Intensive Approaches" International Journal of Molecular Sciences 21, no. 8: 2839.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop